A single high dose of recombinant factor VIIa combining adjuvant therapy for controlling bleeding episodes in haemophiliacs with inhibitors.
A single dose of rFVIIa (150-180 μg/kg) was used to treat five muscle/joint bleeds and to cover 4 minor surgical procedures in 2 patients with hemophilia A and one with hemophilia B with inhibitors. Patients also received prednisolone, in addition to using fibrin glue, dental splint and tranexamic acid with surgical procedures. Treatment was either […]
This is another excellent review of the mechanism of action, indications, and various doses of rFVIIa (Novoseven) in hereditary bleeding disorders. Its main use has been in patients with factor VIII or IX deficiency with inhibitors, where rFVIIa can by-pass factors VIII or IX, interacts with tissue factor and generates thrombin in addition to activating […]